

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 21, 2020

**MYOS RENS TECHNOLOGY INC.**  
(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-53298**  
(Commission File Number)

**90-0772394**  
(IRS Employer  
Identification No.)

**45 Horsehill Road,  
Suite 106 Cedar Knolls, New Jersey**  
(Address of principal executive offices)

**07927**  
(Zip Code)

Registrant's telephone number, including area code **(973) 509-0444**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 Series A Preferred Stock Purchase Rights, \$0.001 par value	MYOS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On September 21, 2020, the board of directors (the “**Board**”) of MYOS RENS Technology Inc. (the “**Company**”) established and confirmed October 2, 2020 as the record date (the “**Record Date**”) for the determination of the holders of common stock, par value \$0.001 per share (“**Common Stock**”), of the Company entitled to receive notice of and to vote at a special meeting of shareholders of the Company (the “**Shareholder Meeting**”), which Shareholder Meeting the Board set for November 10, 2020 at 10:00 a.m. Eastern time, to be held virtually at [www.virtualshareholdermeeting.com/MYOS2020](http://www.virtualshareholdermeeting.com/MYOS2020). The purpose of the Shareholder Meeting is for the Company’s shareholders to consider and vote upon a proposal to approve the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of June 30, 2020 (“**Merger Agreement**”), by and among the Company, Matrix Merger Sub, Inc., a newly-created special purpose subsidiary of the Corporation, and MedAvail, Inc. (“**MedAvail**”), a Delaware corporation (the “**Merger**”) and certain related proposals.

In addition, the Board also established and confirmed October 2, 2020 as the record date for determining the holders of the Company’s Common Stock entitled to receive *pro rata* dividend of all the outstanding shares of common stock of MYOS Corp., a Delaware corporation and a wholly owned subsidiary of Company (the “**Dividend Record Date**”), which shall be distributed at such time as the officers of the Company determine following consummation of the Merger.

*Additional Information and Where to Find It*

The Company has filed with the Securities and Exchange Commission (“**SEC**”), and the parties plan to furnish to the security holders of the Company and MedAvail, a Registration Statement on Form S-4 (“**Form S-4**”), which also will constitute a proxy statement/prospectus of the Company and will be included in an information statement of MedAvail, in connection with the proposed Merger. The proxy statement/prospectus/information statement described above will contain important information about the Company, MedAvail, the proposed Merger and related matters. Investors are urged to read the proxy statement/prospectus/information statement carefully when it becomes available. Investors will be able to obtain free copies of these documents, and other documents filed with the SEC by the Company, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). In addition, investors will be able to obtain free copies of these documents from the Company by going to the Company’s Investor Relations web page at <https://ir.myosrens.com/> and clicking on the link titled “SEC Filings” or by contacting the Company’s Investor Relations group at 973-509-0444 or [jgoodford@myosrenscorp.com](mailto:jgoodford@myosrenscorp.com).

*No Offer or Solicitation*

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

*Participants in the Solicitation*

The respective directors and executive officers of the Company and MedAvail may be deemed to be participants in the solicitation of proxies from the shareholders of the Company and written consent of the stockholders of MedAvail in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the proposed Merger will be included in the proxy statement/prospectus/information statement described above. Additional information regarding the Company’s directors and executive officers is included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 24, 2020, and in the Company’s proxy statement for its 2019 Annual Meeting of Stockholders, which was filed with the SEC on December 5, 2019. These documents are available from the Company free of charge as described above.

---

*Forward Looking Statements*

This communication contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger and the ability of the Company to timely and successfully achieve the anticipated benefits of the Merger. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in the Form S-4 and elsewhere in the Company's most recent filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at [www.sec.gov](http://www.sec.gov). These documents can be accessed on the Company's Investor Relations page at <https://ir.myosrens.com/> by clicking on the link titled "SEC Filings." The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts the Company's and MedAvail's businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

The forward-looking statements included in this communication are made only as of the date hereof. The Company and MedAvail assume no obligation and does not intend to update these forward-looking statements, except as required by law.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 22, 2020

**MYOS RENS TECHNOLOGY INC.**

By: /s/ Joseph Mannello  
Name: Joseph Mannello  
Title: Chief Executive Officer

---